Jiaying Tan: I want to start by asking both of you that, in the past year, which scientific breakthrough outside of your field inspired you the most in terms of how you think of your own research questions and how you pursue them? Mark, do you want to start?
Mark Lemmon: I find it difficult to actually identify a specific breakthrough, I have to say. But as a general movement that I think inspires me, which also comes with a cautionary tale, is the ability of mass spec [trometry] , sequencing, and technological advances as such to collect an awful lot of data on metabolites, protein components, and sequences at the single-cell level. It inspires me in the sense that there's an awful lot of information and an awful lot of detail into which one can delve in the studies. It provides an opportunity for me as a biochemist, as I think about it, to actually start being able to think about the biochemistry in a quantitative way because all of these approaches now are really quantitative, and to really start to put together all of the biochemistry that we've known over the years in a cellular context, that's what inspires me.
There is this fantastic opportunity to use all of these methods quantitatively to address excellent biochemistry questions, and I'll give you some examples, like Josh Rabinowitz's work in looking at metabolic flux and the work of Christian Metallo at UCSD on metabolism. There's a guy named Steve Wiley, who is doing some really interesting work with mass spec now, measuring concentrations of signaling molecules in cells. Those are all papers that came out in the past year.
What worries me, though, is that much of the field isn't using the technology in that way, but instead is using it to get a superficial picture of what exists in the cell in a snapshot type of sense. I think we're at crossroads in some ways, where we need to encourage people to use these technologies to ask quantitative and mechanistic questions because they can do that now. I think that's inspiring. And to avoid the temptation to collect lots of data and superficially interpret them. That's what I've been thinking about a lot over the past year.
JT: That's a very interesting angle. Yossi, do you want to chime in? Joseph (Yossi) Schlessinger: I'll give you a totally different take about how I see things. Of course, I fully agree with what Mark says, but I am sort of inspired to do something specific, usually through guidance from genetic changes. For example, I have been following for many, many years-and this is a topic that influenced me even when I was just in the beginning of my career, and I'm looking for the same theme. Usually, monogenic rare disease that occurs in a few hundreds or sometimes tens of patients tells you a secret that never lies: that there is a critical molecule there, and this is really a human experiment in a way. It's a controlled experiment, to some extent. It tells you that there is this molecule that, out of the blue, it plays a very important role in a particular process, and if you find some other more way to go deeply into it, you realize that, actually, the same product of the genetic change is involved in many other broader diseases in other processes that can be regulated by epigenetic control mechanisms.
For instance, my entire career was changed 40 years ago by reading an article that made me realize that cancer cells need less growth factors because maybe they produce their own or the receptors are already activated. This was a very visionary paper, and I decided to follow it. You see what I'm saying? I'm looking for things like that-not very high tech things, but [that] really unveil a clue that provides you solid foundation on which you can build a story without really having any clue about the process before you read it.
JT: It seems what you are emphasizing is the inherited importance of those disease links with the biochemistry and molecules, the need to have the physiological context to begin with to think of the questions, and earlier studies in other fields that put things into context and guide you to decide where you go with your own research.
JS: When you marry this aspect together with what Mark said, you have a very powerful way of dealing. The monogenic disease is really an experiment, which unfortunately leads into a very bad situation for a particular human being. But once you have this candidate, you can now try to feed this into what Mark proposed. For the first time, they are highly linked. In the past, you can only do the genetic studies or signal biochemistry, but now, you can marry these two approaches and really come up with much more detailed analysis.
ML: Another way of thinking about that is that in some ways, you start with knowing what genetic changes can screw up the cellular organism. You're guaranteed that your change will screw up the networks, screw up the physiology. Whereas, in a sense, the opportunity that I was describingin terms of taking a quantitative broad view of networks, physiology, and biochemistry-there, what you're looking for is an understanding of the system that would potentially allow you to predict what you would need to screw it up. You can see how those would meet in the middle.
JS: Without the element that I proposed, some of the large data analyses are very much risky because there are too many parameters and you may reach the wrong conclusion. What I always say is, genetics doesn't lie. It doesn't tell you the mechanism, but it doesn't lie. You see my point?
JT: Right. I think it's really interesting to see that both of you are very hardcore biochemists in terms of how you approach your own research, yet you gather inspiration from very different angles.
I was curious, Mark, when you mentioned the quantitative view of metabolic influx, and when Yossi, you were mentioning about more of the monogenetic disease aspect. How do you think that change the way you decide what is the next research question that you want to address?
ML: I can give you an example of how my thoughts have changed about this. I grew up as a biochemist when I was trained as an undergraduate in the UK, then [I] started to take a more structural view here. It was when I started working with Yossi [that] I got interested in signaling, but it was really coming from a biochemical perspective. I think one of the papers that really made me change my mind, and developed this network sense that I've been attracted by since, was a paper from Jim Ferrell in Science I think in the late '80s. He did an experiment where he was looking at progesterone-induced maturation of Xenopus oocytes. It's a classic experiment that you now find in textbooks. Basically, if you look at the base response to progesterone in that context, you see a nice curve. As you increase the conservation of progesterone, you see more and more oocyte maturation.
Basically, Jim posed the question: All of the cells are kind of going through a gray zone on their way to maturation as you increase the progesterone. That's one explanation for the shape of the curve. The other is that they all have a very sudden threshold, but their threshold is at different positions. This is just a manifestation of the problem of studying either single cell versus populations of cells. The nice thing with Xenopus oocytes, Jim was one of the first people to do this, was that you can suck the gloop right out of them individually and run it on gel. He showed very nicely in his paper, which is now textbook work, that the cells are either off or on in terms of maturation. That was very inspiring for me to realize the biochemical approach that I would take to look at [how] cells really mislead you about what's going on. You need to think about the circuitry within the individual cells and understand that one cell is different from another, which is different from another. You can only understand those differences if you have a sense of the way the network is configured.
JS: Another example of genetic change in a network is the following one. Ten years ago, I was in a meeting where it was announced that BRAF is mutated in about 50% of melanoma. I very quickly realized that this could be a nice way to develop drugs for treating the disease. Of course, this has happened, and these drugs have been successful, but we quickly find out that these drugs do not work for a long time; there's resistance. Actually, in some contexts, when you block BRAF in a cell that has activated KRAS, you get other types of tumors. Here, we are coming back to networks, because when you block a kinase, you not only block its positive signal, you also block negative feedback signals. But again, everything string started by mutation, which is really driving this cancer, not as a single thing because nevi also had this mutation. So here it is. We are starting from a single change, which is the driver of this cancer together with other things. But in order to cure the disease and have a lasting response, you have to marry all these considerations in order to eliminate negative feedbacks, find mechanisms to eliminate resistance. So it's very practical in addition [to] being conceptually very exciting.
JT: I'm curious, today, when you were teaching your grad students and post-docs in your lab, who are facing a very large number of literature and new papers published every single ML: I don't know, that's a tough question. We do have journal clubs and so forth where people pick papers. I think the guidance is really to ask whether they think something new conceptually is emerging. There are a million papers out there that add a small twist on to our understanding of something that's developed quite rapidly. I think those are the less exciting papers. You can often identify them quite quickly, whereas when you are going through papers published in Cell or wherever, you get a sense quite quickly as to whether a paper is really telling you something new. I mean, you do that for a living, right? In a sense of trying to get people to appreciate that, and then if they find papers where there is a sense that it's telling you something new, to give it the appropriate challenge when they're reading it. That, I think, is the key thing: the exciting, new stuff, rather than ''me, too'' stuff.
JS: The entire attitude toward reading papers and going to libraries changed during my lifetime. Now, almost no one goes to libraries. Everything is being read online, and you are overwhelmed. I have realized that many of my students continually operate through keywords. They're working in my field, so they want to see everything. Many times, they bring to me new papers before I've seen them because I'm not as rigorous as far as searching through keywords. Usually they bring me many of the news.
What I'm trying to tell them is that they have to read broad literature because many times, the thing that is going to be more useful for them and would lead them to further development is a different topic that they have not realized how it's linked to their work. This is very difficult to do these days because first of all, no one goes to libraries; everything occurs between you and the computer, and you're overwhelmed by information. I think we are clearly saturated by information, and it's extremely difficult to grasp the essence and see what topic is going to be most helpful for me and enrich me in a way of my eventual goal of making progress in science. I don't have a magic answer of how to train because this is really changing all the time.
ML: Sure, but I think the general approach of journal clubs is one of the ways that helps training people in this world.
JS: Yes. Someone chooses a particular article, a Cell article, let's say, and we discuss it.
ML: I'd like to get back to one point just following on from Yossi's RAF example. I remember when I was starting my career, I wondered whether I wanted to work on the effects of drugs on cellular signaling because I thought, is that science or is it not science? It's quite interesting when I look back at that thought and then look back at what we have learned about RAS-RAF-MAP kinase signaling, about EGF receptor signaling, about lots of elements from the studies of drugs. You know, we would never understand the rather complex networks surrounding BRAF if people hadn't seen the effects of dabrafenib and the other BRAF inhibitors in the clinic and then studied them in the labs. That's a great example of reverse translational research that I've always quite liked to point to.
JS: Which started from a genetic change. ML: Yes, absolutely. Another example of how we started from a set of genetic changes was the EGF receptor. 13 years ago, my lab and several others published papers on the structure of EGF receptor, several of them in Cell and Molecular Cell. One of the things that we really couldn't figure out was how on earth the kinase was regulated by ligandinduced dimerization. This is getting down to the nitty-gritty structure, but the absolute key for understanding that ended up being the EGF receptor inhibitors that were applied in phase II clinical trials at that point. The subset of patients that responded had a bunch of mutations that you only found in those patients. They responded dramatically, and again, through a process of reverse translational research that went back to biochemical and structural studies, we understood, really, [that] it was those mutations that explained how that kinase worked. It's been very interesting that [the] reverse translational component, I think, has become such at a crucial part. Yossi is absolutely right, it comes precisely from the genetics of us trying to understand these networks and pathways.
JS: The young generation, unless they are really trained in genetics, is really impressed by the large scale of data analysis and all those and the idea that everything can be done by computers. I'm trying to provide these people the information that monogenic disease or [a] case like that is actually an experiment, which leads to unfortunate disease. You don't see it that way among the young generation, and I think this is something that they're always surprised when I tell them. I think this is important to remember.
ML: I agree 100%, and I think that with the vast amounts of data that are collected, there is this belief among the-I'll age myself in saying this-Twitter or Facebook generation that you can understand very large quantities of data of the sort that I was mentioning, including sequences, proteomics, and metabolomics, and you can understand it using statistics. I think that's impossible. I think you can only understand it through mechanistic considerations, so essentially, what I'm arguing therefore is that what you need to do when you're analyzing these large data sets is essentially put yourself in the same mindset that you would use if you're thinking about genetic changes. In other words, you need to go back up the same road from the data as you would come down from a genetic change, which is going back to the link between the approaches that we would consider.
JT: Right. I think that's very important, especially in the big data era, when there's a lot of analyses going on, tons of data coming out of all kinds of analyses all the time, I completely agree that it can be overwhelming, and we should be very cautious in terms of how to interpret the data and how to extrapolate.
JS: You have to link it to reality here. When you have a genetic change, this is reality because it causes a disease.
ML: You have to use the data, not be used by the data, I think. JT: That's a very good way to put it. It's really inspiring to see how the two of you from [a] very similar background think of science in such a holistic and integrated way and then put both disease context and the most recent technical advance together, marrying them in light of the big data analysis and using this view to guide the future research. I think it's more important than ever for the PIs [principle investigators] to have the vision to guide the next generation in terms of how you do journal club. That's a very important venue to pass this idea of how to think things conceptually and how to think things integratively and to make the most of the technical advance and information components out there, but not be used by them.
ML: Indeed. JS: Indeed.
